Immuron Ltd
Business
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company developing and commercializing orally delivered targeted polyclonal antibody therapeutics for inflammatory-mediated and infectious gastrointestinal diseases. It offers marketed hyperimmune bovine colostrum products Travelan and Protectyn and is developing clinical-stage candidates (IMM-124E/Travelan for travelers’ diarrhea and IMM-529 for C. difficile) alongside discontinued and other research programs. Business segments include commercial consumer products, clinical-stage drug development, and manufacturing of hyperimmune colostrum-based APIs. It sells through pharmacies, online retailers and distributors and collaborates with U.S. military research partners.
Summary from filing dated 2025-09-25
Financials
Latest annual snapshot (FY2025, period end 2025-06-30). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-5.22M |
| Total assets | $10.13M |
| Total liabilities | $2.06M |
| Stockholders' equity | — |
| Operating cash flow | — |